Abstract Library

#3016 DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance

Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Liverani C

Authors: Liverani C, Bongiovanni A, Pieri F, Foca F, Ravaioli S,

Keywords: DLL3, RB1, prognostic biomarker, GEP-NEN,

#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

#2162 Single Cell Copy Number Variation Analysis (CNV) of Circulating Tumor Cells (CTCs) in Neuroendocrine Tumor (NET) Patients

Introduction: The identification and characterization of CTCs as part of a minimally invasive “liquid biopsy” provides an opportunity to explore NET biology, identify therapeutic targets and investigate tumour heterogeneity.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Childs A

Authors: Childs A, Vesely C, Rizzo F, Ensell L, Lowe H,

Keywords: CTCs, tumor heterogeneity, CNV,

#2116 Ghrelin O-Acyltransferase (GOAT) Enzyme and Ghrelin Receptor GHSR1a as Putative Prognosis Markers and Therapeutic Targets in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Specific components of ghrelin-system are associated with tumor development/ progression. We have previously described the presence of this system in neuroendocrine tumors (NETs) but clinical-molecular correlations have not been elucidated yet.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martinez A

Authors: Herrera-Martínez A, Gahete M, Sánchez-Sánchez R, Ortega Salas R, Serrano R,

Keywords: GEP-NET, ghrelin system, GOAT, GHSR1a, prognosis, invasion,

#1891 GSK3: A Novel Therapeutic Target in NETs?

Introduction: GSK3 is a serine/threonine-kinase that plays a critical role in cancer. In neuroendocrine tumours (NETs) GSK3 is regularly overactivated.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Nölting S

Authors: Weis C, Aristizabal Prada E, Maurer J, Spöttl G, Grossman A,

Keywords: GSK3-inhibition, neuroendocrine tumors, combination treatment,